Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis : a randomised, placebo-controlled, double-blind trial
Journal
Gut
Volume
59
Number
1
Pages / Article-Number
21-30
Abstract
Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated.
